Improving accountability in vaccine decision-making
暂无分享,去创建一个
[1] N. Dickert,et al. Justifying Clinical Nudges. , 2017, The Hastings Center report.
[2] R. Rappuoli,et al. Core values for vaccine evaluation. , 2017, Vaccine.
[3] S. Ozawa,et al. Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States. , 2016, Health affairs.
[4] E. Nicod. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries , 2016, The European Journal of Health Economics.
[5] Jane J. Kim,et al. Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. , 2016, Gynecologic oncology.
[6] L. Callahan,et al. Item response theory analysis of Centers for Disease Control and Prevention Health-Related Quality of Life (CDC HRQOL) items in adults with arthritis , 2016, Health and Quality of Life Outcomes.
[7] Zoltán Kaló,et al. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] Maarten J. IJzerman,et al. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[9] A. Sherwood,et al. Does Conditional Marketing Authorisation Influence Market Access in France, England, and Germany? , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[10] Mirjam Knol,et al. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community , 2015, PharmacoEconomics.
[11] N. MacDonald. Vaccine hesitancy: Definition, scope and determinants. , 2015, Vaccine.
[12] H. Larson,et al. Measuring vaccine hesitancy: The development of a survey tool. , 2015, Vaccine.
[13] D. Bloom. Valuing vaccines: deficiencies and remedies. , 2015, Vaccine.
[14] Glennis A. Logsdon,et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality , 2015, Science.
[15] D. Levy-bruhl,et al. Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[16] Karl Claxton,et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.
[17] M. Drummond,et al. Comparison of NITAG policies and working processes in selected developed countries. , 2015, Vaccine.
[18] R. Sanson-Fisher,et al. Health research priority setting in selected high income countries: a narrative review of methods used and recommendations for future practice , 2014, Cost Effectiveness and Resource Allocation.
[19] S. Black. Potential long term vaccine benefits poorly translate in cost effectiveness modelling , 2014, BMJ : British Medical Journal.
[20] W. Edmunds,et al. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study , 2014, BMJ : British Medical Journal.
[21] Marc Fleurbaey,et al. Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis , 2014, Cost Effectiveness and Resource Allocation.
[22] Till Bärnighausen,et al. Valuing vaccination , 2014, Proceedings of the National Academy of Sciences.
[23] R. Baltussen,et al. Legitimate Healthcare Limit Setting in a Real-World Setting: Integrating Accountability for Reasonableness and Multi-Criteria Decision Analysis , 2014 .
[24] C. Reh. Is informal politics undemocratic? Trilogues, early agreements and the selection model of representation , 2014 .
[25] J. Raftery,et al. NICE’s Cost-Effectiveness Range: Should it be Lowered? , 2014, PharmacoEconomics.
[26] Bruce Y. Lee,et al. Reassessing the value of vaccines. , 2014, The Lancet. Global health.
[27] Anne Peters. The Transparency of Global Governance , 2014 .
[28] Mike Paulden,et al. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] Jenny de Fine Licht,et al. When Does Transparency Generate Legitimacy? Experimenting on a Context‐Bound Relationship , 2014 .
[30] S. Black. The role of health economic analyses in vaccine decision making. , 2013, Vaccine.
[31] O. Wichmann,et al. National Advisory Groups and their role in immunization policy-making processes in European countries. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[32] S. Omer,et al. Epidemiology of vaccine hesitancy in the United States , 2013, Human vaccines & immunotherapeutics.
[33] J. Mekalanos. Vaccine Economics: What Price Human Life? , 2013, Science Translational Medicine.
[34] Philip R. Johnson,et al. Accelerating Next-Generation Vaccine Development for Global Disease Prevention , 2013, Science.
[35] Matthew Hickman,et al. Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact , 2013, Vaccine.
[36] D. Fryback,et al. Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint , 2013 .
[37] J. Frenk,et al. Governance challenges in global health. , 2013, The New England journal of medicine.
[38] M. Jit,et al. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies , 2013, Human vaccines & immunotherapeutics.
[39] A. Dowsett. The price of prevention: what now for immunisation against meningococcus B? , 2013 .
[40] Rob Baltussen,et al. Mapping of multiple criteria for priority setting of health interventions: an aid for decision makers , 2012, BMC Health Services Research.
[41] K. Marsh,et al. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods , 2012, Health Economics Review.
[42] Jane J. Mansbridge. Clarifying the Concept of Representation , 2011, American Political Science Review.
[43] D. Canning,et al. The effect of vaccination on children's physical and cognitive development in the Philippines , 2011 .
[44] P. Rota,et al. Health care-associated measles outbreak in the United States after an importation: challenges and economic impact. , 2011, The Journal of infectious diseases.
[45] N. Devlin,et al. Incorporating Multiple Criteria in HTA: Methods and Processes , 2011 .
[46] S. J. Whitehead,et al. Health outcomes in economic evaluation: the QALY and utilities. , 2010, British medical bulletin.
[47] M. Jit,et al. A brief history of economic evaluation for human papillomavirus vaccination policy. , 2010, Sexual health.
[48] David Barnett,et al. Pharmacoeconomics: NICE's approach to decision-making. , 2010, British journal of clinical pharmacology.
[49] B. Gessner,et al. Informing decision makers: experience and process of 15 National Immunization Technical Advisory Groups. , 2010, Vaccine.
[50] J. Bryson,et al. A systematic review of national immunization policy making processes. , 2010, Vaccine.
[51] S. Grosse. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold , 2008, Expert review of pharmacoeconomics & outcomes research.
[52] Sue J Goldie,et al. Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches. , 2008, PharmacoEconomics.
[53] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[54] G. Carrin,et al. Clarifying Efficiency-Equity Tradeoffs Through Explicit Criteria, With a Focus on Developing Countries , 2005, Health Care Analysis.
[55] Jane J. Mansbridge. The fallacy of tightening the reins , 2005 .
[56] M. Little. Setting limits fairly: can we learn to share medical resources? , 2004 .
[57] Douglas K. Martin,et al. Fairness, accountability for reasonableness, and the views of priority setting decision-makers. , 2002, Health policy.
[58] Norman Daniels,et al. Setting Limits Fairly: Can We Learn to Share Medical Resources? , 2002 .
[59] H. Glick,et al. Economic Evaluation of Vaccination Programmes , 2002, PharmacoEconomics.
[60] Robert O. Keohane,et al. Global Governance and Democratic Accountability , 2002 .
[61] H. Glick,et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. , 2002, PharmacoEconomics.
[62] Bruce E. Barrett,et al. The efficacy of SMARTER — Simple Multi-Attribute Rating Technique Extended to Ranking , 1996 .
[63] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[64] E. P. Seskin,et al. The economic value of life: linking theory to practice. , 1982, American journal of public health.
[65] G. Psacharopoulos. Rates of Return to Investment in Education around the World , 1972, Comparative Education Review.